Status:
RECRUITING
Obstetrical History and Anti-HLA Antibodies Level
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Etablissement Français du Sang (Nouvelle Aquitaine)
Conditions:
Blood Donors
Anti-HLA Antibody
Eligibility:
FEMALE
18+ years
Brief Summary
Chronic histiocytic intervillositis (CHI) is associated with severe and recurrent obstetrical complications. A link between anti-HLA Antibodies (Ab) and CHI has recently been established. At the Etabl...
Detailed Description
Chronic histiocytic intervillositis (CHI) is a rare condition with an incidence of around 5 in 10,000 pregnancies. It is defined by major infiltration of the intervillous cavity by CD68+ maternal hist...
Eligibility Criteria
Inclusion
- Female blood donors who have been tested for anti-HLA antibodies in the context of TRALI prevention between 2010 and 2020 at EFS Nouvelle Aquitaine \[The donors meet the conditions of the Order of December 17, 2019 establishing the selection criteria for blood donors and are over 18 years old, are not protected persons and understand French well\]
- Women who have already given birth at least once (non-nulliparous women)
- Women who have not expressed their opposition at the time of donation to participating in a research project and to be contacted
Exclusion
- None \[Donors meet the conditions of the Order of December 17, 2019 establishing the selection criteria for blood donors and are over 18 years old, are not protected persons and understand French well\]
Key Trial Info
Start Date :
December 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 13 2024
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT06021925
Start Date
December 13 2023
End Date
June 13 2024
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Etablissement Français du Sang Nouvelle Aquitaine
Bordeaux, France, 33075